Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Positive grass allergy tablet data from Merck as advisory meeting looms

This article was originally published in Scrip

Executive Summary

Merck has reported positive results for its Timothy grass sublingual immunotherapy tablet (MK-7243), licensed from ALK, including pediatric data. The BLA for the product was filed in January this year, and accepted for review in March (, 28 March 2013). Merck expects the US FDA's review for to be completed in the first half of 2014, but has not released the PDUFA date.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts